IOBTQ (IO Biotech) Total Receivables: $0.99 Mil (As of Sep. 2025)


What is IO Biotech Total Receivables?

IO Biotech IOBTQ +27.50% Total Receivables is $0.99 Mil as of Sep. 2025. The stock has 1 warning sign investors should review.

IO Biotech's Total Receivables for the quarter that ended in Sep. 2025 was $0.99 Mil.

IO Biotech Total Receivables Historical Data

* Premium members only.

The historical data trend for IO Biotech's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IO Biotech Total Receivables Chart

IO Biotech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Receivables
Get a 7-Day Free Trial 1.50 2.09 1.53 1.13 1.13

IO Biotech Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.96 1.13 0.92 1.14 0.99

IO Biotech Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $0.99 Mil mean?
IO Biotech (IOBTQ) has a Total Receivables of $0.99 Mil as of Sep. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on IO Biotech and its competitors.
Is IO Biotech's Total Receivables too high?
IO Biotech's current Total Receivables is $0.99 Mil.
How does IO Biotech's Total Receivables compare to CNBX and ENDV?
IO Biotech's Total Receivables of $0.99 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on IO Biotech and its competitors. IO Biotech's current Total Receivables is $0.99 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IO Biotech stock overvalued right now?
IO Biotech (IOBTQ) has a current Total Receivables of $0.99 Mil. The current Total Receivables is $0.99 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For IO Biotech (IOBTQ), the current Total Receivables is $0.99 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

IO Biotech Business Description

Address Ole Maaloes Vej 3, Copenhagen N, DNK, DK-2200
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.